Cochrane Infectious Diseases Group, UK

Main interests

The CIDG’s main areas of work are on determination of the effects of interventions on the prevention or treatment of infectious diseases of relevance to the United Nations Sustainable Development Goals, particularly malaria, tuberculosis, HIV/AIDS, and neglected tropical diseases in low- and middle-income countries.

The aims of the CIDG are to impact on policy and research in tropical diseases through the production of high quality and relevant systematic reviews and to lead developments in review quality improvement and effective dissemination of findings.

The CIDG:

  • has over 700 active authors from around the world currently preparing or updating Cochrane systematic reviews.
  • includes 20 international Editors, Co-ordinating Editor, Managing Editor, Statistician, Information Specialists, Editorial Assistants, and Specialist Advisors.
  • provides training and support for author teams in preparing and updating reviews, and methodological help in all aspects of research synthesis, including preparing 'Summary of findings' tables.

Current publications

Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID‐19 disease (February 2021)

Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19 (February 2021)

House modifications for preventing malaria (January  2021)

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (January 2021)

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria (January 2021)

Hand‐washing promotion for preventing diarrhoea (January 2021)

Probiotics for treating acute infectious diarrhoea (December 2020)

Thoracic imaging tests for the diagnosis of COVID‐19 (November 2020)

Routine laboratory testing to determine if a patient has COVID‐19 (November 2020)

Rapid diagnostic tests for Plasmodium vivax malaria in endemic countries (November 2020)

Quarantine alone or in combination with other public health measures to control COVID‐19: a rapid review (September 2020)

Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (August 2020)

Rapid, point‐of‐care antigen and molecular‐based tests for diagnosis of SARS‐CoV‐2 infection (August 2020)

Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax (August 2020)

Treating progressive disseminated histoplasmosis in people living with HIV (August 2020)

ARRIVE guidelines 2.0 (July 2020)

Rapid diagnostic tests for plague (June 2020) Guiding plague prevention and treatment: an atypical journey

Antibody tests for identification of current and past infection with SARS‐CoV‐2 (June 2020)

Hand cleaning with ash for reducing the spread of viral and bacterial infections: a rapid review (April 2020)

Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV‐positive individuals (September 2019)

Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (September 2019)

Larviciding to prevent malaria transmission  (August 2019)

WHO interim guidelines for the treatment of gambiense human African trypanosomiasis (August 2019) 

Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (June 2019)

Rapid initiation of antiretroviral therapy for people living with HIV (June 2019)

Indoor residual spraying for preventing malaria in communities using insecticide‐treated nets (May 2019)

MVA85A vaccine to enhance BCG for preventing tuberculosis (April 2019)

Other publications and stories

Ventilation Techniques and Risk for Transmission of Coronavirus Disease, Including COVID-19 (May 2020)

WHO guidance for refugees in camps: systematic review (September 2019)